• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Ask the Expert / Anti CCP antibodies and the treatment of RA with only a few joints affected

Anti CCP antibodies and the treatment of RA with only a few joints affected

December 31, 2008 By Clifton Bingham, III, MD

Question

I was diagnosed with RA about 3 years ago. My diagnosis was based on positive anti-CCP and RF (out of range). I had about 2 tender joints at diagnosis. I had no morning stiffness; ESR and CRP were normal (and still normal); and ANA negative. I am taking MTX (10 mg qw). Do I really have RA? Thank you, Kala

Answer

Kala, this is a very good question and one that we are dealing with more and more these days. The anti CCP antibody is to date our most SPECIFIC marker for the disease of rheumatoid arthritis, with a specificity of > 99%.  We now understand that this test can become positive years before the first signs of rheumatoid arthritis joint swelling.  While not detected in all patients with RA, when the CCP antibody is present, we know that this test also indicates patients at higher risk of joint damage.  Based on the results of several studies in patients with very early RA with only a few swollen and tender joints who have a positive anti-CCP antibody, we have seen that initiation of methotrexate can decrease the numbers of patients that go on to be classified as rheumatoid arthritis and also decreases XRay damage. Others have used hydroxychloroquine (Plaquenil). I hope at this point that your arthritis is under control.  We usually will continue to monitor X-Rays of the joints every year or so.  In patients who have had an initial and sustained response (eg “remission” of their arthritis) on medication, we may then consider tapering back medications. Sometimes this is possible, but in our experience, more often than not, the disease begins to come back.  Through research we hope to better understand the early triggers of the disease, the biomarkers that may help to determine the best drugs, and ultimately a true “cure” for RA.   

Clifton Bingham, III, MD

Professor of Medicine
Director - Johns Hopkins Arthritis Center

Primary Sidebar

Ask The Expert Topics

  • Alternative Therapies
  • Ankylosing Spondylitis
  • Associated With Other Illnesses
  • Bursitis and Tendinitis
  • Corticosteroids
  • Diet and Exercise
  • Disease Modifying Antirheumatic Drugs (DMARDs)
  • Enteropathic Arthritis
  • Fibromyalgia
  • General Arthritis
  • Gout, Pseudogout, Other
  • Infectious Arthritis
  • Myositis
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Osteoarthritis
  • Osteonecrosis
  • Osteoporosis
  • Polymyalgia Rheumatica
  • Psoriatic Arthritis
  • Reactive Arthritis
  • Regional Pain: Back and Neck
  • Rehabilitation
  • Rheumatoid Arthritis
  • Surgical Therapy
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis
  • Vasculitis
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy